Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy

About this update from Remegen Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Remegen Co. Ltd. Class A